Live feed08:01:00·552dPRReleasevia QuantisnowIntellia Presents Positive Results from the Phase 2 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)ByQuantisnow·Wall Street's wire, on your screen.NTLA· Intellia Therapeutics Inc.Health Care
